Screening for hepatitis B virus infection in adolescents and adults: A systematic review to update the U.S. Preventive Services Task Force recommendation

Roger Chou, Tracy Dana, Christina Bougatsos, Ian Blazina, Jessi Khangura, Bernadette Zakher

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: In 2004, the U.S. Preventive Services Task Force (USPSTF) recommended against screening for hepatitis B virus (HBV) infection. Purpose: To update the 2004 USPSTF review on screening for HBV infection in adolescents and adults. Data Sources: MEDLINE (through January 2014), the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and PsycINFO. Study Selection: Randomized trials of screening and treatment and observational studies of screening or the association between intermediate and clinical outcomes after antiviral therapy. Data Extraction: One investigator abstracted data, and a second investigator checked them; 2 investigators independently assessed study quality. Data Synthesis: No study directly evaluated the effects of screening for HBV infection versus no screening on clinical outcomes. Vaccination against HBV infection was associated with decreased risk in high-risk populations. On the basis of 11 primarily fairquality trials, antiviral therapy may be more effective than placebo for reducing the risk for clinical outcomes associated with HBV infection. However, differences were not statistically significant. On the basis of 22 primarily fair-quality trials, antiviral therapy was more effective than placebo for various intermediate outcomes, with limited evidence that first-line antiviral agents are superior to lamivudine. Antiviral therapy was associated with a higher risk for withdrawal due to adverse events than placebo, but risk for serious adverse events did not differ. Limitation: Only English-language articles were included, clinical outcome data for antiviral therapies were limited, and several studies were done in countries where the prevalence and natural history of HBV infection differ from those of the United States. Conclusion: Antiviral treatment for chronic HBV infection is associated with improved intermediate outcomes, but more research is needed to understand the effects of screening and subsequent interventions on clinical outcomes and to identify optimal screening strategies.

Original languageEnglish (US)
Pages (from-to)31-45
Number of pages15
JournalAnnals of Internal Medicine
Volume161
Issue number1
DOIs
StatePublished - Jul 1 2014

Fingerprint

Virus Diseases
Advisory Committees
Hepatitis B virus
Antiviral Agents
Placebos
Research Personnel
Therapeutics
Lamivudine
Information Storage and Retrieval
Chronic Hepatitis B
Natural History
MEDLINE
Observational Studies
Vaccination
Language
Outcome Assessment (Health Care)
Databases
Population

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Screening for hepatitis B virus infection in adolescents and adults : A systematic review to update the U.S. Preventive Services Task Force recommendation. / Chou, Roger; Dana, Tracy; Bougatsos, Christina; Blazina, Ian; Khangura, Jessi; Zakher, Bernadette.

In: Annals of Internal Medicine, Vol. 161, No. 1, 01.07.2014, p. 31-45.

Research output: Contribution to journalArticle

Chou, Roger ; Dana, Tracy ; Bougatsos, Christina ; Blazina, Ian ; Khangura, Jessi ; Zakher, Bernadette. / Screening for hepatitis B virus infection in adolescents and adults : A systematic review to update the U.S. Preventive Services Task Force recommendation. In: Annals of Internal Medicine. 2014 ; Vol. 161, No. 1. pp. 31-45.
@article{33493b31e56c4edf9edfe394e1fbf9b9,
title = "Screening for hepatitis B virus infection in adolescents and adults: A systematic review to update the U.S. Preventive Services Task Force recommendation",
abstract = "Background: In 2004, the U.S. Preventive Services Task Force (USPSTF) recommended against screening for hepatitis B virus (HBV) infection. Purpose: To update the 2004 USPSTF review on screening for HBV infection in adolescents and adults. Data Sources: MEDLINE (through January 2014), the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and PsycINFO. Study Selection: Randomized trials of screening and treatment and observational studies of screening or the association between intermediate and clinical outcomes after antiviral therapy. Data Extraction: One investigator abstracted data, and a second investigator checked them; 2 investigators independently assessed study quality. Data Synthesis: No study directly evaluated the effects of screening for HBV infection versus no screening on clinical outcomes. Vaccination against HBV infection was associated with decreased risk in high-risk populations. On the basis of 11 primarily fairquality trials, antiviral therapy may be more effective than placebo for reducing the risk for clinical outcomes associated with HBV infection. However, differences were not statistically significant. On the basis of 22 primarily fair-quality trials, antiviral therapy was more effective than placebo for various intermediate outcomes, with limited evidence that first-line antiviral agents are superior to lamivudine. Antiviral therapy was associated with a higher risk for withdrawal due to adverse events than placebo, but risk for serious adverse events did not differ. Limitation: Only English-language articles were included, clinical outcome data for antiviral therapies were limited, and several studies were done in countries where the prevalence and natural history of HBV infection differ from those of the United States. Conclusion: Antiviral treatment for chronic HBV infection is associated with improved intermediate outcomes, but more research is needed to understand the effects of screening and subsequent interventions on clinical outcomes and to identify optimal screening strategies.",
author = "Roger Chou and Tracy Dana and Christina Bougatsos and Ian Blazina and Jessi Khangura and Bernadette Zakher",
year = "2014",
month = "7",
day = "1",
doi = "10.7326/M13-2837",
language = "English (US)",
volume = "161",
pages = "31--45",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "1",

}

TY - JOUR

T1 - Screening for hepatitis B virus infection in adolescents and adults

T2 - A systematic review to update the U.S. Preventive Services Task Force recommendation

AU - Chou, Roger

AU - Dana, Tracy

AU - Bougatsos, Christina

AU - Blazina, Ian

AU - Khangura, Jessi

AU - Zakher, Bernadette

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Background: In 2004, the U.S. Preventive Services Task Force (USPSTF) recommended against screening for hepatitis B virus (HBV) infection. Purpose: To update the 2004 USPSTF review on screening for HBV infection in adolescents and adults. Data Sources: MEDLINE (through January 2014), the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and PsycINFO. Study Selection: Randomized trials of screening and treatment and observational studies of screening or the association between intermediate and clinical outcomes after antiviral therapy. Data Extraction: One investigator abstracted data, and a second investigator checked them; 2 investigators independently assessed study quality. Data Synthesis: No study directly evaluated the effects of screening for HBV infection versus no screening on clinical outcomes. Vaccination against HBV infection was associated with decreased risk in high-risk populations. On the basis of 11 primarily fairquality trials, antiviral therapy may be more effective than placebo for reducing the risk for clinical outcomes associated with HBV infection. However, differences were not statistically significant. On the basis of 22 primarily fair-quality trials, antiviral therapy was more effective than placebo for various intermediate outcomes, with limited evidence that first-line antiviral agents are superior to lamivudine. Antiviral therapy was associated with a higher risk for withdrawal due to adverse events than placebo, but risk for serious adverse events did not differ. Limitation: Only English-language articles were included, clinical outcome data for antiviral therapies were limited, and several studies were done in countries where the prevalence and natural history of HBV infection differ from those of the United States. Conclusion: Antiviral treatment for chronic HBV infection is associated with improved intermediate outcomes, but more research is needed to understand the effects of screening and subsequent interventions on clinical outcomes and to identify optimal screening strategies.

AB - Background: In 2004, the U.S. Preventive Services Task Force (USPSTF) recommended against screening for hepatitis B virus (HBV) infection. Purpose: To update the 2004 USPSTF review on screening for HBV infection in adolescents and adults. Data Sources: MEDLINE (through January 2014), the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and PsycINFO. Study Selection: Randomized trials of screening and treatment and observational studies of screening or the association between intermediate and clinical outcomes after antiviral therapy. Data Extraction: One investigator abstracted data, and a second investigator checked them; 2 investigators independently assessed study quality. Data Synthesis: No study directly evaluated the effects of screening for HBV infection versus no screening on clinical outcomes. Vaccination against HBV infection was associated with decreased risk in high-risk populations. On the basis of 11 primarily fairquality trials, antiviral therapy may be more effective than placebo for reducing the risk for clinical outcomes associated with HBV infection. However, differences were not statistically significant. On the basis of 22 primarily fair-quality trials, antiviral therapy was more effective than placebo for various intermediate outcomes, with limited evidence that first-line antiviral agents are superior to lamivudine. Antiviral therapy was associated with a higher risk for withdrawal due to adverse events than placebo, but risk for serious adverse events did not differ. Limitation: Only English-language articles were included, clinical outcome data for antiviral therapies were limited, and several studies were done in countries where the prevalence and natural history of HBV infection differ from those of the United States. Conclusion: Antiviral treatment for chronic HBV infection is associated with improved intermediate outcomes, but more research is needed to understand the effects of screening and subsequent interventions on clinical outcomes and to identify optimal screening strategies.

UR - http://www.scopus.com/inward/record.url?scp=84903598615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903598615&partnerID=8YFLogxK

U2 - 10.7326/M13-2837

DO - 10.7326/M13-2837

M3 - Article

C2 - 24861032

AN - SCOPUS:84903598615

VL - 161

SP - 31

EP - 45

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 1

ER -